Findings hold promise for developing regenerative therapies for spinal cord injuries and diseases such as multiple sclerosis
Stem cell technology has long offered the hope of regenerating tissue to repair broken or damaged neural tissue. Findings from a team of UC Davis investigators have brought this dream a step closer by developing a method to generate functioning brain cells that produce myelin — a fatty, insulating sheath essential to normal neural conduction.
“Our findings represent an important conceptual advance in stem cell research,” said Wenbin Deng, principal investigator of the study and associate professor at the UC Davis Department of Biochemistry and Molecular Medicine. “We have bioengineered the first generation of myelin-producing cells with superior regenerative capacity.”
The brain is made up predominantly of two cell types: neurons and glial cells. Neurons are regarded as responsible for thought and sensation. Glial cells surround, support and communicate with neurons, helping neurons process and transmit information using electrical and chemical signals. One type of glial cell — the oligodendrocyte — produces a sheath called myelin that provides support and insulation to neurons. Myelin, which has been compared to insulation around electrical wires that helps to prevent short circuits, is essential for normal neural conduction and brain function; well-recognized conditions involving defective myelin development or myelin loss include multiple sclerosis and leukodystrophies.
In this study, the UC Davis team first developed a novel protocol to efficiently induce embryonic stem cells (ESCs) to differentiate into oligodendroglial progenitor cells (OPCs), early cells that normally develop into oligodendrocytes. Although this has been successfully done by other researchers, the UC Davis method results in a purer population of OPCs, according to Deng, with fewer other cell types arising from their technique.
They next compared electrophysiological properties of the derived OPCs to naturally occurring OPCs. They found that unlike natural OPCs, the ESC-derived OPCs lacked sodium ion channels in their cell membranes, making them unable to generate spikes when electrically stimulated. Using a technique called viral transduction, they then introduced DNA that codes for sodium channels into the ESC-derived OPCs. These OPCs then expressed ion channels in their cells and developed the ability to generate spikes.
According to Deng, this is the first time that scientists have successfully generated OPCs with so-called spiking properties. This achievement allowed them to compare the capabilities of spiking cells to non-spiking cells.
In cell culture, they found that only spiking OPCs received electrical input from neurons, and they showed superior capability to mature into oligodendrocytes.
They also transplanted spiking and non-spiking OPCs into the spinal cord and brains of mice that are genetically unable to produce myelin. Both types of OPCs had the capability to mature into oligo-dendrocytes and produce myelin, but those from spiking OPCs produced longer and thicker myelin sheaths around axons.
“We actually developed ‘super cells’ with an even greater capacity to spike than natural cells,” Deng said. “This appears to give them an edge for maturing into oligodendrocytes and producing better myelin.”
It is well known that adult human neural tissue has a poor capacity to regenerate naturally. Although early cells such as OPCs are present, they do not regenerate tissue very effectively when disease or injury strikes.
Deng believes that replacing glial cells with the enhanced spiking OPCs to treat neural injuries and diseases has the potential to be a better strategy than replacing neurons, which tend to be more problematic to work with. Providing the proper structure and environment for neurons to live may be the best approach to regenerate healthy neural tissue. He also notes that many diverse conditions that have not traditionally been considered to be myelin-related diseases – including schizophrenia, epilepsy and amyotrophic lateral sclerosis (ALS) – actually are now recognized to involve defective myelin.
The Latest Bing News on:
Stem cell technology
- What is the technology behind a five minute rechargeable battery?on January 23, 2021 at 11:27 am
What is the technology behind a five minute rechargeable battery? Building a better battery requires addressing issues in materials ...
- Europe Fuel Cell Technology Market Growth, Size, Opportunity, Share and Forecast 2019-2025on January 23, 2021 at 8:30 am
The European fuel cell market is expected to grow at a CAGR of over 14 98 during 2019 2025 Automotive and portable applications are the major drivers of fuel cells in the market In addition Europe has ...
- What’s the technology behind a five-minute charge battery?on January 23, 2021 at 5:00 am
So, it was exciting to see that a company called StoreDot that was claiming the development of a battery that would allow five-minute charging of electric vehicles was apparently willing to talk to ...
- Stem Cell & Regenerative Medicine Market Size, Share, Trends, Growth Insight, Share, Competitive Analysis, Statistics, Regional And Forecaston January 22, 2021 at 7:13 pm
Jan (AmericaNewsHour) -- The report titled "Global Stem Cell & Regenerative Medicine Market Outlook: Industry Demand Analysis & ...
- The Global Stem Cell Market Estimated to Reach $16782.2 Million in Revenue by 2028on January 22, 2021 at 4:21 am
According to Triton s report the global stem cell market which garnered 9382 million in 2020 is predicted to advance at 7 54 of CAGR by 2028 A recent study by Triton Market Research titled Global Stem ...
- Hydrogen and Fuel Cells: The Future of Mobility?on January 21, 2021 at 4:00 pm
As part of Cowen and Company’s “Energy Transition Series,” analysts spoke with The Hydrogen Council Executive Director Daryl Wilson to explore the adoption of hydrogen and fuel cell technologies—from ...
- Using CRISPR technology, team tracks lineage of individual cancer cells as they proliferate and metastasize in real timeon January 21, 2021 at 11:11 am
When cancer is confined to one spot in the body, doctors can often treat it with surgery or other therapies. Much of the mortality associated with cancer, however, is due to its tendency to ...
- CRISPR technology to cure sickle cell diseaseon January 21, 2021 at 9:36 am
University of Illinois Chicago is one of the U.S. sites participating in clinical trials to cure severe red blood congenital diseases such as sickle cell anemia or Thalassemia by safely modifying the ...
- Temple spinoff Express Cells secures first patent for gene-editing technologyon January 20, 2021 at 6:19 pm
A three-year-old Philadelphia genetic engineering company spun out of Temple University has secured its first patent for its core gene-editing technology. ExpressCells was awarded the U.S. patent for ...
- BP partner StoreDot produces cells with 5-minute fast charging technologyon January 20, 2021 at 10:49 am
News Highlights: BP partner StoreDot produces cells with 5-minute fast charging technology Isareli startup StoreDot has long promised a holy grail of ...
The Latest Google Headlines on:
Stem cell technology
The Latest Bing News on:
Regenerative therapies for spinal cord injuries and diseases
- The Global Stem Cell Market Estimated to Reach $16782.2 Million in Revenue by 2028on January 22, 2021 at 4:21 am
According to Triton s report the global stem cell market which garnered 9382 million in 2020 is predicted to advance at 7 54 of CAGR by 2028 A recent study by Triton Market Research titled Global Stem ...
- Lineage Posts Series of Webinars Highlighting Recent Progress With its Three Clinical-Stage Allogeneic Cell Transplant Programson January 21, 2021 at 10:00 am
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to address ...
- Kar?na Narbute's research in extracellular vesicles earns her Young Investigator Awardon January 21, 2021 at 7:50 am
Kar?na Narbute, Ph.D. is the latest recipient of STEM CELLS Translational Medicine's Young Investigator Award.
- Stem Cells Market to Reach USD 17.78 Billion | Global Size Analysis, Segmentation, Industry Outlook, and Forecasts 2021-2027on January 20, 2021 at 3:37 am
Increasing occurrence of diseases and surging adoption of stem cell therapies are fueling the market growth. Market size: USD 9.35 billion in 2019 Market ...
- Paralyzed Mice Walk Again after Treatment with Designer Cytokineon January 15, 2021 at 3:30 pm
In mice, loss of hindlimb motion due to spinal cord injury was significantly reversed by DNA encoding hyper-interleukin-6 (hIL-6), a designer cytokine. The DNA was delivered by an adeno-associated ...
- New Drug Delivery System Targets Spinal Cord Injurieson January 14, 2021 at 10:16 pm
Young Hye Song, assistant professor of biomedical engineering, has been awarded a grant to improve treatments for spinal cord injuries by developing a new drug delivery method using stem cells.
- Electromagnetic stimulation may improve arm and hand function after spinal cord injuryon January 14, 2021 at 9:39 am
We are very interested in testing the effectiveness of this novel and non-invasive approach in persons with spinal cord injury, Such interventions may improve participants' performance of activities ...
- Stem Cells Market to Touch USD 18,289.9 Million during 2020 to 2027, Owing to Increasing Adoption of Stem Cells for the Treatment of Various Diseaseson January 6, 2021 at 11:36 pm
Stem cell therapy is also known as regenerative medicine ... Stem cell therapies are used in the treatment of spinal cord injury, Parkinson’s disease, sickle cell disease, diabetes, and heart ...
- Spinal Cord Injuryon December 29, 2020 at 4:00 pm
A spinal cord injury (SCI) refers to any injury to the spinal cord that is caused by trauma instead of disease ... which means a total loss of function. Treatment of spinal cord injuries starts ...
- Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injuryon December 8, 2020 at 12:00 am
A spinal cord injury (SCI ... grant from the California Institute for Regenerative Medicine. OPC1 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation ...